Gamma-delta T-cell lymphomas

Nature Reviews Clinical Oncology

Volumn 6, Issue 12, 2009, Pages 707-717

  Tripodo, Claudio ^a   Iannitto, Emilio ^a   Florena, Ada Maria ^a   Pucillo, Carlo Ennio ^b   Piccaluga, Pier Paolo ^c   Franco, Vito ^a   Pileri, Stefano Aldo ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; METHOTREXATE; PENTOSTATIN; PLATINUM COMPLEX; PREDNISONE; STEROID; VINCRISTINE;

ABDOMINAL DISCOMFORT; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CAPILLARY RESISTANCE; CLINICAL FEATURE; CLINICAL TRIAL; COOMBS POSITIVE HEMOLYTIC ANEMIA; CYTOGENETICS; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG FATALITY; DRUG MEGADOSE; FATIGUE; FEVER; HEPATOMEGALY; HEPATOSPLENIC T CELL LYMPHOMA; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INFECTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE STRUCTURE; LYMPHOCYTIC INFILTRATION; MOLECULAR BIOLOGY; PANNICULITIS; PATHOGENESIS; PRIMARY CUTANEOUS GAMMA DELTA T CELL LYMPHOMA; PRIORITY JOURNAL; PURPURA; REMISSION; REVIEW; SKIN DEFECT; SPLENECTOMY; SPLENOMEGALY; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; WEAKNESS; WEIGHT REDUCTION; CUTANEOUS T CELL LYMPHOMA; GENE REARRANGEMENT; GENETICS; PERIPHERAL T CELL LYMPHOMA;

CLINICAL TRIALS AS TOPIC; GENE REARRANGEMENT, DELTA-CHAIN T-CELL ANTIGEN RECEPTOR; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMA, T-CELL, PERIPHERAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA;

EID: 75649084946     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.169     Document Type: Review

References (87)

1. Armitage, J., Vose, J. & Weisenburger, D. International peripheral T-cell and natural killer/ T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124-4130 (2008).
2. Swerdlow, S. H et al. (eds) World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (IARC, Lyon, 2008).
3. Piccaluga, P. P. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 117, 823-834 (2007).
4. Agostinelli, C. et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J. Clin. Pathol. 61, 1160-1167 (2008).
5. Ciofani, M., Knowles, G. C., Wiest, D. L., von Boehmer, H. & Zúñiga-Pflücker, J. C. Stagespecific and differential Notch dependency at the αβ and γδ T lineage bifurcation. Immunity 25, 105-116 (2006).
6. Denning, S. M. & Haynes, B. F. Differentiation of human T cells. Clin. Lab. Med. 8, 1-14 (1988).
7. Havran, W. L. & Boismenu, R. Activation and function of γδ T cells. Curr. Opin. Immunol. 6, 442-446 (1994).
8. Sayers, T. J. et al. The restricted expression of granzyme M In human lymphocytes. J. Immunol. 166, 765-771 (2001).
9. Chattopadhyay, P. K. et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 85, 88-97 (2009).
10. Inghirami, G., Zhu, B. Y., Chess, L. & Knowles, D. M. Flow cytometric and immunohistochemical characterization of the γ/δ T-lymphocyte population in normal human lymphoid tissue and peripheral blood. Am. J. Pathol. 136, 357-367 (1990 (Pubitemid 20074610)
11. Falini, B. et al. Distribution of T cells bearing different forms of the T cell receptor γ/δ in normal and pathological human tissues. J. Immunol. 143, 2480-2488 (1989 (Pubitemid 19260052)
12. Moser, B. & Eberl, M. γδ T cells: novel initiators of adaptive immunity. Immunol. Rev. 215, 89-102 (2007). (Pubitemid 46212232)
13. Groh.V.Steinle, A., Bauer S. & Spies, T. Recognition of stress-induced MHC molecules by Intestinal epithelial γδ T cells. Science 279, 1737-1740 (1998 (Pubitemid 28164472)
14. Brandes, M., Willimann, K. & Moser, B. Professional antigen-presentation function by human γδ T cells. Science 309, 264-268 (2005 (Pubitemid 40967855)
15. Schild, H. et al. The nature of major histocompatibility complex recognition by γδ T cells. Cell 76, 29-37 (1994 (Pubitemid 2040162)
16. Chien, Y. H. & Konigshofer, Y. Antigen recognition by γδ T cells. Immunol. Rev. 215, 46-58 (2007).
17. + T regulatory cells in mycobacterial infection. Blood 113, 837-845 (2009).
18. + γδ T cells control early Infiltration of neutrophils after Escherichia coli infection via IL-17 production. J. Immunol. 178, 4466-4472 (2007).
19. Toth, B. et al. The role of γδ T cells in the regulation of neutrophil-mediated tissue damage after thermal injury. J. Leukoc. Biol. 76, 545-552 (2004 (Pubitemid 39129085)
20. Jensen, K. D. Thymic selection determines γδ T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon γ. Immunity 29, 90-100 (2008).
21. Przybylski, G. K. et al. Hepatosplenic and subcutaneous panniculitis-like γ/δ T cell lymphomas are derived from different Vδ subsets of γ/δ T lymphocytes. J. Mol. Diagn. 2, 11-19 (2000).
22. Tey, S. K., Marlton, P. V., Hawley, C. M., Noms, D. & Gill, D. S. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am. J. Hematol. 83, 330-333 (2008).
23. Khan, W. A. et al. Hepatosplenic γ/δ T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am. J. Clin. Pathol. 116, 41-50 (2001).
24. Knowles, D. M. et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85, 552-565 (1995).
25. Vilmer, E. et al. Prominent expansion of circulating lymphocytes bearing γ T-cell receptors, with preferential expression of variable γ genes after allogeneic bone marrow transplantation. Blood 72, 841-849 (1988).
26. Kronenberg, M. & Havran, W. L. Frontline T cells: γδ T cells and intraepithelial lymphocytes. Immunol. Rev. 215, 5-7 (2007).
27. Ross, C. W., Schnitzer, B., Sheldon, S., Braun, D. K. & Hanson, C. A. γ/δ T-cell posttransplantation lymphoprollferative disorder primarily In the spleen. Am. J. Clin. Pathol. 102, 310-315 (1994 (Pubitemid 24330990)
28. Belhadj, K. et al. Hepatosplenic γδ T-cell lymphoma is a rare clinlcopathologic entity with poor outcome: report on a series of 21 patients. Blood 102, 4261-4269 (2003 (Pubitemid 37494082)
29. Mackey, A. C., Green, L., Liang, L. C., Dinndorf, P. &Avlgan, M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44, 265-267 (2007 (Pubitemid 46175082)
30. Shale, M., Kanfer, E., Panaccione, R. & Ghosh, S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57, 1639-1641 (2008).
31. US Food and Drug Administration The Adverse Event Reporting System (AERS): Latest Quarterly Data Files [online], http://www.fda.gov/cder/ aers/extract.htm (2009).
32. Toro, J. R. et al. γ δ T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch. Dermatol. 136, 1024-1032 (2000).
33. Arnulf, B. et al. Nonhepatosplenlc γδ T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 91, 1723-1731 (1998 (Pubitemid 28110338)
34. Farcet, J. P et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor γ δ. Blood 75, 2213-2219 (1990 (Pubitemid 20181173)
35. Gaulard, P., Belhadj, K. & Reyes, F. γδ T-cell lymphomas. Semin. Hematol. 40, 233-243 (2003).
36. Falchook, G. S. et al. Hepatosplenic γ-δ T-cell lymphoma: clinicopathological features and treatment. Ann. Oncol. 20, 1080-1085 (2009).
37. Weidmann, E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14, 991-997 (2000).
38. Florena, A. M., Iannltto, E., Quintini, G. & Franco, V. Bone marrow biopsy in hemophagocytic syndrome. Virchows Arch. 441, 335-344 (2002 (Pubitemid 36015596)
39. Burg, G. et al. A subcutaneous δ-posltive T-cell lymphoma that produces interferon γ- N. Engl. J. Med. 325, 1078-1081 (1991).
40. Nosari, A. et al. Hepato-splenic γδ T-cell lymphoma: a rare entity mimicking the hemophagocytic syndrome. Am. J. Hematol. 60, 61-65(1999 (Pubitemid 28565853)
41. Mazodier, K. et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106, 3483-3489 (2005 (Pubitemid 41609184)
42. Wang, C. Y., Su, W. P.& Kurtin, P.J. Subcutaneous pannlculltic T-cell lymphoma. Int. J. Dermatol. 35, 1-8 (1996).
43. Kumar, S. et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum. Pathol. 29, 397-403 (1998 (Pubitemid 28231906)
44. Toro, J. R. et al. γ-δ T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101, 3407-3412 (2003).
45. Willemze, R. et al. EORTC Cutaneous Lymphoma Group. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111, 838-845 (2008).
46. Vega, F., Medeiros, L. J. & Gaulard, P. Hepatosplenic and other γδ T-cell lymphomas. Am. J. Clin. Pathol. 127, 869-880 (2007).
47. Salhany, K. E. et al. Hepatosplenic γδ T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum. Pathol. 28, 674-685 (1997).
48. Sallah, S. et al. γ/δ T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann. Hematol. 74, 139-142 (1997 (Pubitemid 27182326)
49. Falini, B. et al. T-lymphoblastic lymphomas expressing the non-disulfide-linked form of the T-cell receptor γ/δ: characterization with monoclonal antibodies and genotypic analysis. Blood 74, 2501-2507 (1989 (Pubitemid 19286472)
50. + phenotype justify the Identification of a new subtype? Description of two cases and review of the literature. Ann. Oncol. 10, 649-653 (1999).
51. Massone, C. et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, Immunophenotypic, and molecular study of 50 patients. Am. J. Surg. Pathol. 28, 719-735 (2004).
52. Go, R. S. & Wester, S. M. immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitls-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 101, 1404-1413 (2004).
53. Gaulard, P. et al. Expression of the α/β and γ/δ T-cell receptors In 57 cases of peripheral T-cell lymphomas. identification of a subset of γ/δ T-cell lymphomas. Am. J. Pathol. 137, 617-628 (1990).
54. Cooke, C. B. et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic γ δ T-cell origin. Blood 88, 4265-4274 (1996).
55. de Wolf-Peeters, C. & Achten, R. γδ T-cell lymphomas: a homogeneous entity? Histopathology 36, 294-305 (2000).
56. Allory, Y. et al. Bone marrow involvement in lymphomas with hemophagocytlc syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am. J. Surg. Pathol. 25, 865-874 (2001).
57. Gaulard, P. et al. Peripheral T-cell lymphoma presenting as predominant liver disease: a report of three cases. Hepatology 6, 864-868 (1986).
58. Florena, A. M. et al. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk. Lymphoma 47, 49-57 (2006).
59. Mastovich, S., Ratech, H., Ware, R. E., Moore, J. O. & Borowitz, M. J. Hepatosplenic T-cell lymphoma: an unusual case of a γ δ T-cell lymphoma with a blast-like terminal transformation. Hum. Pathol. 25, 102-108 (1994).
60. Vega, F. et al. Hepatosplenic γ/δ T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am. J. Clin. Pathol. 116, 410-419(2001).
61. Boulland.M. L., Kanavaros, P., Wechsler, J., Caslraghi, O. & Gaulard, P. Cytotoxic protein expression in natural killer cell lymphomas .nd in α β and γ δ peripheral T-cell lymphomas. J. Pathol. 183, 432-439 (1997).
62. Suarez, F. et al. Hepatosplenic αβ T-cell lymphoma: an unusual case with clinical histologic, and cytogenetic features of γδ hepatosplenic T-cell lymphoma. Am. J. Surg. Pathol. 24, 1027-1032 (2000).
63. Macon, W. R. Hepatosplenic αβ T-cell lymphomas: a report of 14 cases and comparison with hepatosplenlc γδ T-cell lymphomas. Am. J. Surg. Pathol. 25, 285-296 (2001).
64. Wang, C. C. et al. Consistent presence of isochromosome 7q in hepatosplenic T γ/δ lymphoma: a new cytogenetic-clinlcopathologic entity. Genes Chromosomes Cancer 12, 161-164 (1995).
65. Wlodarska. I. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 33, 243-251 (2002).
66. Jonveaux, P., Daniel, M. T., Martel, V., Maarek, O. & Berger, R. Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T γ/δ lymphoma. Leukemia 10, 1453-1455 (1996).
67. Tamaska, J. et al. Hepatosplenlc γδ T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration. Virchows Arch. 449, 479-483 (2006).
68. Alonsozana, E. L. et al. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic γδ T cell lymphoma. Leukemia 11, 1367-1372 (1997).
69. Miyazaki, K. et al. Gene expression profiling of peripheral T-cell lymphoma including γδ T-cell lymphoma. Blood 113, 1071-1074 (2009).
70. + T-Cell malignancies. Br. J. Haematol. 110, 188-196 (2000).
71. Iannitto, E., Barbera, V., Quintini, G., Clrrincione, S. & Leone, M. Hepatosplenic γδ T-cell lymphoma: complete response induced by treatment with pentostatin. Br. J. Haematol. 117, 995-996 (2002).
72. Corazzelli, G. et al. Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic γδ T-cell lymphomas. Haematologica 90, ECR14 (2005).
73. Macor, P. & Tedesco, F. Complement as effector system in cancer immunotherapy. Immunol. Lett. 111, 6-13(2007).
74. Macor, P. et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67, 10556-10563 (2007).
75. 1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nel Linfomi) prospective multicenter trial. Blood 110, 2316-2323 (2007).
76. Mittal, S., Milner, B. J., Johnston, P.W. & Culligan, D. J. A case of hepatosplenic γ-δ T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur. J. Haematol. 76, 531-534(2006).
77. Jaeger, G. et al. Hepatosplenic γδ T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann. Oncol. 19, 1025-1026 (2008).
78. Ferrarini, M. et al. NF-κB modulates sensitivity to apoptosls, proinflammatory and migratory potential In short-versus long-term cultured human γ δ lymphocytes. J. Immunol. 181, 5857-5864 (2008).
79. Koenecke, C. et al. In vivo application of mAb directed against the γδ TCR does not deplete but generates "invisible" γδ T cells. Eur. J. Immunol. 39, 372-379 (2009).
80. Hathaway, T., Subtil, A., Kuo, P. & Foss, F. Efficacy of denileukin diftitoxin subcutaneous panniculltis-like T-cell lymphoma. Clin. Lymphoma Myeloma 7, 541-545 (2007).
81. Vidulich, K., Jones, D. & Duvic, M. Cutaneous γ/δ T-cell lymphoma treated with radiation and denileukin diftitox. Clin. Lymphoma Myeloma 8, 55-58 (2008).
82. H2 lymphocytes to roll and adhere. Blood 107, 4798-4806 (2006).
83. Bonneville, M. & Scotet, E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18, 539-546(2006).
84. + γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 14, 4232-4240 (2008).
85. Thedrez, A. et al. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vγ 9V δ2 T cells for adoptive immunotherapy. J. Immunol. 182, 3423-3431 (2009).
86. Martinet, L. et al. A regulatory cross-talk between Vγ9Vδ2 T lymphocytes and mesenchymal stem cells. Eur. J. Immunol. 39, 752-762 (2009).
87. Henter, J. I., Elinder, G. & Ost, A. Diagnostic guidelines for hemophagocytic lymphohlstiocytosis. The FHL Study Group of the Histiocyte Society. Semin. Oncol. 18, 29-33 (1991).